Contents 5 dk okuma
Anatomical image showing omega-3 DHA and EPA neuron membrane, myelin support, inflammation reduction, synaptic plasticity and mood circuitry.
The Omega-3 diagram combines DHA-derived membrane flexibility with EPA-derived inflammation control in the same brain structure.

What are Omega-3 DHA and EPA?

Omega-3 fatty acids are a family of polyunsaturated fatty acids that the human body cannot synthesize on its own and must be obtained from the diet. The two most critical members in terms of nootropic DHA (docosahexaenoic acid, 22:6n-3) and EPA (eicosapentaenoic acid, 20:5n-3). Both are found primarily in fatty marine fish (salmon, sardines, anchovies) and algae.

DHA is the most dominant structural fatty acid of the human brain. DHA constitutes the majority of phospholipid membranes in the cerebral cortex and retina; therefore, it is indispensable for neuronal function. EPA, on the other hand, stands out mainly with its anti-inflammatory effects and plays a critical role in mood regulation. Because modern Western diets dramatically overload omega-6 fatty acids over omega-3 (ratio 15:1–20:1, ideal ratio ~4:1), nearly all modern humans are chronically deficient in DHA and EPA.

Mechanism of Effect

Omega-3 DHA/EPA phospholipid membrane fluidity, anti-inflammatory signaling, myelin, and mood circuit mechanism diagram.
Mechanism focus: DHA membrane structure, EPA inflammation balance, and synaptic flexibility.

Effects of omega-3s on the brain; It occurs through structural, anti-inflammatory and neurotrophic mechanisms, and the fact that they constantly interact with each other explains why these fatty acids are an essential supplement.

Cell membrane fluidity and structure: DHA is incorporated into neuron membranes and increases the fluidity of the membrane. This feature allows receptors to work more efficiently and neurotransmitter release to occur faster. This structural feature, which is the basis of synaptic transmission, shows how fundamental DHA is for cognitive function.

Anti-inflammatory eicosanoid synthesis: EPA and DHA competitively suppress the conversion of arachidonic acid to inflammatory prostaglandins and leukotrienes. In addition, it turns into anti-inflammatory signaling molecules called resolvins and protectins. This effect is of great importance, as chronic neuroinflammation is strongly associated with depression, Alzheimer's, and neuronal aging.

BDNF and serotonin system support: DHA contributes to the production of BDNF (Brain Derived Neurotrophic Factor); this effect supports neuroplasticity and learning capacity. EPA, on the other hand, plays a critical role in mood regulation through effects on the serotonin system; It increases serotonin release and increases serotonin receptor density.

Fatty AcidPrimary MechanismMain Effect
DHA (22:6)Neuron membrane structure, BDNF increaseNeuroplasticity, cognitive structure, visual function
EPA (20:5)Anti-inflammatory eicosanoid synthesis, serotonin modulationDecreased mood, neuroinflammation
DHA + EPAResolvin/protectin productionActive neuroprotection, resolution of inflammation

Clinical Evidence

Grosso et al. (2014) In the meta-analysis conducted by , 13 RCTs and 1233 participants were examined; It was concluded that omega-3 supplementation (especially formulations with high EPA content) significantly reduced symptoms of depression compared to placebo. Although the effect size is moderate (d ≈ 0.3–0.5), it is consistent enough to attract the attention of clinicians.

Su et al. (2003)published a small-scale, double-blind, placebo-controlled study showing that 8 weeks of omega-3 supplementation (6.6 g EPA+DHA per day) provided statistically significant improvements in depression scores compared to placebo in patients with major depressive disorder.

Yurko-Mauro et al. (2010)reported that 24 weeks of high-dose DHA supplementation (900 mg/day) in elderly individuals resulted in significant improvement compared to placebo on tests of episodic memory and learning; The study authors likened this effect to the cognitive performance of individuals several years younger.

The critical importance of DHA in terms of neurodevelopment is supported by much stronger evidence: Adequate DHA intake during pregnancy and breastfeeding has a decisive effect on children's cognitive development, visual acuity and attention scores.

⚠ Form and Quality Differences Are Important

The total omega-3 content of fish oil supplements on the market can be misleading. It's not the "total fish oil" that matters, but the sum of the EPA and DHA amounts on the label. The freshness of these oils, which are sensitive to oxidation, is critical; A fishy smell may be a sign of oxidation. For vegans, algae-based DHA/EPA supplements should be preferred.

Dosage Protocol

When reading the label of omega-3 supplements, the total amount of EPA + DHA should be checked; fish oil capsule weight can be much higher than this.

Intended UseEPA + DHA DosageNotes
General brain health (protective)1–1.5 g/dayWith fatty food; morning or evening
Mood and depression support2–3 g/day (EPA predominant)EPA:DHA ≥ 2:1 ratio is preferred
Neuroprotection and anti-inflammation2–4 g/dayDHA based formula may be preferred
Pregnancy and breastfeedingMin. 200 mg DHA/dayWith doctor's recommendation; algae based safe

Form selection: Omega-3s in the triglyceride (rTG) form have been shown to be up to 70% more bioavailable than the ethyl ester (EE) form. For a quality supplement, the phrase "re-esterified triglyceride" should be looked for. For vegans, microalgae DHA is the preferable option both from an environmental and safety perspective.

Safety and Side Effects

Omega-3 supplementation is generally very well tolerated; It is one of the most widely used supplements around the world.

Who Does It Interact With?

Sources

  1. Grosso G, et al. (2014). Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxidative Medicine and Cellular Longevity, 2014, 313570. PubMed · PMID 24757497
  2. Su KP, et al. (2003). Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology, 13(4), 267–271. PubMed · PMID 12888186
  3. Yurko-Mauro K, et al. (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's & Dementia, 6(6), 456–464. Search PubMed (match unverified)
  4. Calder PC (2016). Docosahexaenoic acid. Annals of Nutrition and Metabolism, 69(Suppl 1), 7–21. Search PubMed (match unverified)
  5. Freeman MP, et al. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry, 67(12), 1954–1967. PubMed · PMID 17194275

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions